Assessing Cognitive Safety of Drugs in Clinical Development

Key Discussion Points:

• What is cognition and how is it best measured throughout the drug development process for both CNS and non-CNS indications?
• Why monitor cognition in drug development?
• Are there current or upcoming regulations that impact cognition assessment?
• What are desirable characteristics of cognitive assessment tools?
• What developments are on the horizon for cognitive assessment?

Spend 60 minutes with two industry experts and walk away with a firm understanding of why there is a need to assess cognitive safety in clinical development of compounds, the methodological considerations for cognitive assessment in clinical trials, approaches to the analysis and interpretation of cognitive outcome measures and how current state-of-the-art cognitive assessment technology can be incorporated into the clinical development process to facilitate early decision making, evaluate cognitive efficacy, profile safety and tolerability and satisfy regulatory requirements in an increasingly challenging and competitive pharmaceutical landscape.

Featured Speakers:

• Pradeep Nathan, MA, PhD, MRACI, CChem, FCP, Vice President Neuroscience Scientific Strategy Lead and Head, Neuroscience Center of Innovation, inVentiv Health
• Kenton H. Zavitz, PhD, Director of Clinical Affairs , Cambridge Cognition, Ltd.